Non-proliferative Diabetic Retinopathy Clinical Trial
Official title:
Effects of a Novel Dietary Supplement on Visual Function in Patients With Diabetes With and Without Early Diabetic Retinopathy
This study will evaluate the effects of a novel multi-component dietary supplement on the
visual function and retinal structure of patients with diabetes with both no diabetic
retinopathy and mild to moderate diabetic retinopathy. This is a placebo-controlled trial
and neither subjects nor examiners will know if any given subject is taking active
supplement or placebo.
The hypothesis is that the supplement will improve visual function and retinal structure in
subjects on active supplement
Adult patients with either type 1 or type 2 diabetes will be enrolled with baseline measurement of visual acuity, contrast sensitivity, color vision, threshold macular perimetry, macular pigment optical density, optical coherence tomography, glycosylated hemoglobin, blood lipids and serum vitamin D status. A multi-component dietary supplement containing ingredients currently available over the counter in the US will be taken for six months and repeat measurements of the above parameters obtained. ;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04511715 -
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT02388984 -
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
|
Phase 3 | |
| Not yet recruiting |
NCT01107132 -
Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus
|
N/A | |
| Active, not recruiting |
NCT05681884 -
Safety and Efficacy of Faricimab in Patients With NPDR
|
Phase 2 | |
| Recruiting |
NCT06270836 -
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
|
Phase 3 | |
| Completed |
NCT01872611 -
Nepafenac Once Daily for Macular Edema - Study 2
|
Phase 3 | |
| Completed |
NCT01853072 -
Nepafenac Once Daily for Macular Edema - Study 1
|
Phase 3 | |
| Completed |
NCT02096874 -
Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema
|
Phase 4 | |
| Not yet recruiting |
NCT04000789 -
The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR)
|
N/A | |
| Active, not recruiting |
NCT05695417 -
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
|
Phase 1 | |
| Recruiting |
NCT05222633 -
Anti-VEGF in Real-world
|
||
| Completed |
NCT02062034 -
Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy
|
Phase 2 | |
| Completed |
NCT02435862 -
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
|
Phase 2 | |
| Terminated |
NCT05066230 -
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
|
Phase 3 | |
| Not yet recruiting |
NCT06428825 -
A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure
|
Phase 1 | |
| Active, not recruiting |
NCT05393284 -
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
|
Phase 2 | |
| Completed |
NCT01571232 -
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
|
Phase 2 |